The expression of microRNA-31 in esophageal squamous cell carcinoma and its prognostic value

罗君; 凌志强; 彭兵锋; 袁嘉敏; 郑智国; 毛伟敏

doi:10.3969/j.issn.1007-3969.2013.07.002

您当前的位置：

首页 >

文章列表页 >

The expression of microRNA-31 in esophageal squamous cell carcinoma and its prognostic value

更新时间：2025-12-31

- The expression of microRNA-31 in esophageal squamous cell carcinoma and its prognostic value
- China Oncology Vol. 23, Issue 7, Pages: 487-492(2013)
- 作者机构：
  
  浙江省肿瘤医院，浙江省肿瘤研究所，浙江省胸部肿瘤( 肺、食管) 诊治技术研究重点实验室,浙江,杭州,310022
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.07.002
  CLC：
- Published Online：03 March 2014，
  
  Published：2013
- 稿件说明：
移动端阅览
罗君,凌志强,彭兵锋,袁嘉敏,郑智国,毛伟敏. MicroRNA-31在食管鳞状细胞癌中的表达及其与预后的关系[J]. 中国癌症杂志, 2013, 23(7): 487-492.

罗君, 凌志强, 彭兵锋, et al. The expression of microRNA-31 in esophageal squamous cell carcinoma and its prognostic value[J]. China Oncology, 2013, 23(7): 487-492.
罗君,凌志强,彭兵锋,袁嘉敏,郑智国,毛伟敏. MicroRNA-31在食管鳞状细胞癌中的表达及其与预后的关系[J]. 中国癌症杂志, 2013, 23(7): 487-492. DOI： 10.3969/j.issn.1007-3969.2013.07.002.

罗君, 凌志强, 彭兵锋, et al. The expression of microRNA-31 in esophageal squamous cell carcinoma and its prognostic value[J]. China Oncology, 2013, 23(7): 487-492. DOI： 10.3969/j.issn.1007-3969.2013.07.002.

摘要

背景与目的：研究发现，许多微小RNA(microRNAs，miRNAs)与恶性肿瘤密切相关，其中miR-31(microRNA-31)在许多肿瘤中呈异常改变。中国是食管鳞状上皮细胞癌(esophageal squamous cell carcinoma，ESCC)最高发的地区之一。本研究旨在调查miR-31在ESCC中的表达水平与临床病理学因素以及预后的关系。方法：采用实时反转录聚合酶链反应(reverse transcription-polymerase chain reaction，RTPCR)技术检测食管癌细胞株KYSE410、EC1和EC9706，以及81例ESCC组织和癌旁正常组织中miR-31的表达水平。结果与临床资料和随访结果结合作统计分析。结果：在3株ESCC细胞株以及75.31%的ESCC组织中，miR-31表达上调。并且miR-31的高表达与更严重的淋巴结转移(P=0.043)、更深的浸润深度(P=0.002)以及更晚期的病理分期有关(P=0.027)，而与其他临床病理学因素无关(P0.05)。此外，miR-31的高表达与较差的无进展生存期(progression-free survival，PFS)有关(Kaplan-Meier分析P=0.014，多变量Cox分析P=0.021)。结论：miR-31可能是ESCC一项新的诊断和预后评价指标。

Abstract

Background and purpose: It was reported that many microRNAs (miRNAs) have close relation with carcinomas. miR-31 (microRNA-31) shows abnormal change in numerous cancers. China is one of the most high-risk areas of esophageal squamous cell carcinoma (ESCC). The aim of the present study was to investigate the expression of miR-31 in ESCC

and analyze the relationship of its expression with clinicopathological features and prognosis. Methods: The expression of miR-31 in KYSE410

EC1 and EC9706 cell lines

as well as 81 cases of ESCC tissues and adjacent normal esophageal tissues were detected by real-time reverse transcription-polymerase chain reaction (RT-PCR). The result was combined with clinical and follow-up data and statistical analysis was conducted. Results: MiR-31 was up-expression in 3 cell lines and 75.31% of the ESCC tissues. miR-31 up-expression was positively related to severer lymph node metastasis (P=0.043)

deeper invasion of tumors (P=0.002) and advanced pathological stage (P=0.027). There was no relationship of miR-31 with other clinicopathological features (P0.05). Furthermore

high expression of miR-31 was associated with poor progression-free survival (PFS) in 81 ESCC patients by Kaplan-Meier analysis (P=0.014) and by multivariate Cox analysis (P=0.021). Conclusion: Our results identified miR-31 may be a new diagnostic criteria and prognostic biomarker for ESCC.

关键词

Keywords

references

Views

2193

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma

Consistency analysis of PD-L1 immunohistochemistry antibodies in esophageal squamous cell carcinoma

SRSF1 promotes proliferation, invasion and migration of esophageal squamous cell carcinoma Eca9706 cells by regulating VEGFA mRNA alternative splicing

miR-203a-3p inhibits cell proliferation and invasion of esophageal squamous cell carcinoma by targeting GATA6

The role and mechanism ofNRAGEin radioresistance of human esophageal cancer cells

Related Author

Daiyuan MA

Yang PENG

Ziyi LIAO

Beilei ZENG

Yingying MA

Li ZENG

Kelun GAN

Lijun CHEN

Related Institution

Department of Medical Oncology, Affiliated Hospital of Chuanbei Medical College, Nanchong

Department of Pathology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

河北医科大学第四医院肿瘤免疫科

湖北民族大学附属民大医院消化内科

湖北民族大学附属民大医院肿瘤科

AI问答

⁰